Quoin Pharmaceuticals Reports $15.8 Million Net Loss and Advances QRX003 Clinical Development

Quoin Pharmaceuticals, Ltd. has reported significant financial developments in its latest 10-K filing, revealing a net loss of approximately $15.8 million for the fiscal year ending December 31, 2025, compared to a net loss of $9.0 million in the previous year. This increase in losses, amounting to $6.8 million, is attributed primarily to a substantial rise in research and development expenses, which surged by 172% to approximately $9.8 million, driven by costs associated with clinical studies for its lead product, QRX003, aimed at treating Netherton Syndrome. General and administrative expenses also rose by 9.5% to about $6.5 million, reflecting increased public company expenses and legal fees.

In terms of operational progress, Quoin Pharmaceuticals is advancing its clinical development of QRX003, which is currently undergoing pivotal registrational testing under an open Investigational New Drug (IND) application with the FDA. The company has opened six clinical sites in the U.S. and is expanding its international presence with sites in the UK, Spain, France, and the Netherlands. Additionally, QRX003 is being tested in pediatric patients in several countries, including Ireland and New Zealand. The company has also entered into multiple research agreements, including a collaboration with Queensland University of Technology for QRX008, a potential treatment for scleroderma.

Quoin's strategic initiatives have led to the establishment of nine commercial partnerships for QRX003 across 61 countries, extending its reach beyond core markets in the U.S., Western Europe, and Japan. The company is also preparing to commercialize QRX003 by building its own sales infrastructure in key markets and working with distribution partners in other regions. Despite these advancements, the company has yet to generate any revenue, as it has not yet commercialized any products.

As of December 31, 2025, Quoin reported cash and cash equivalents totaling $3.8 million, alongside investments of $14.9 million. The company acknowledges substantial doubt about its ability to continue as a going concern for at least one year from the issuance of its financial statements, emphasizing the need for additional funding to support ongoing operations and development activities. Quoin plans to explore various financing options, including public or private offerings, collaborations, and strategic partnerships, to secure the necessary capital for its future endeavors.

Looking ahead, Quoin Pharmaceuticals aims to complete the late-stage clinical testing of QRX003 and submit for marketing approval in the U.S., Europe, and Japan, contingent on successful trial outcomes. The company is also focused on expanding its product pipeline and pursuing additional research and development opportunities to address unmet medical needs in rare and orphan diseases.